Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide
复制标题
DOI：
10.1046/j.1365-2141.2002.03409.x
复制
发表时间：
2002-04-01
影响因子：
6.5
通讯作者：
Kwong, YL
中科院分区：
文献类型：
--
作者：
Au, WY;Chim, CS;Kwong, YL
对于复发的急性早幼粒细胞白血病(APL)，用三氧化二砷(As2O3)成功治疗的最佳治疗方案尚未确定。对3例三氧化二砷诱导缓解后复发的急性早幼粒细胞白血病患者进行研究。在第三次复发中，1例患者用三氧化二砷再次治疗失败，另一例患者在形态上得到缓解，但在分子上没有缓解。然而，三氧化二砷和全反式维甲酸(ATRA)联合治疗后，3例患者的形态和分子水平均得到缓解，随访时间为6~16个月。我们的结果提示三氧化二砷和全反式维甲酸对晚期复发的急性早幼粒细胞白血病有协同治疗作用。
The optimal treatment of acute promyelocytic leukaemia (APL) recurring from relapses successfully treated using arsenic trioxide (As2O3 ) is undefined. Three APL patients relapsing from As2O3-induced remission were studied. Re-treatment with As2O3 failed in one patient in third relapse, and resulted in morphological but not molecular remission in another patient. Combination therapy with As2O3 and all-trans retinoic acid (ATRA), however, resulted in morphological and molecular remission in all three cases, with a follow-up time ranging from 6 to 16 months. Our results suggest a synergistic therapeutic effect between As2O3 and ATRA in APL in advanced relapse.